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ASBMT POSITION STATEMENT
Joint Public Policy on Legislative and
Regulatory Affairs
ADOPTED BY:
American Society for Blood and Marrow Transplantation
American Association of Blood Banks
Foundation for the Accreditation of Cellular Therapy
International Bone Marrow Transplant Registry/Autologous Blood and Marrow Transplant Registry
International Society for Cellular Therapy
National Marrow Donor Program
Blood and marrow transplantation is a cellular therapy that encompasses the collection, processing, and infusion of hematopoietic
progenitor cells derived from peripheral blood, cord blood, and bone marrow. The ﬁeld is represented by several national and
international organizations that have the common purpose of achieving the best possible outcomes of patient care and advancing
knowledge and understanding in this highly specialized and rapidly evolving medical ﬁeld.
Although each organization has its own speciﬁc objectives, particular constituency, and priorities, all share a common set of values
and beliefs. It is because of these shared values that the blood and marrow transplant community can set forth a uniﬁed agenda for
public policy.
The underlying principle and bedrock belief upon which all other positions are based is that . . .
Patients in need of a blood or marrow transplant and their transplant donors have a right to appropriate, high-quality medical care.
This principle is the foundation supporting the following corollary beliefs.
1. Access to Care
Patients and donors should have access to appro-
priate transplant therapy irrespective of socioeco-
nomic or geographic limitations. No patient should be
denied life-saving therapy.
2. Cost of Care
The cost of blood and marrow transplantation
procedures for accepted indications should be appro-
priately reimbursed.
Donors should not be liable for the costs of do-
nation.
3. Patient and Donor Rights
Patients and donors have the right to make deci-
sions about their own care and a right to the informa-
tion needed to make those decisions.
The transplant patient has a right to give consent
based on clear information about each step of the
transplantation process, the associated risks and ben-
eﬁts, and any reasonable alternatives.
The transplant donor has a right to give consent
based on clear information about the donation proce-
dures and the risks and beneﬁts of each step of the
registration and donation process. No individual
should be coerced or pressured to become a donor or
join a donor registry.
4. Confidentiality
Patients and donors have a right to privacy. The
identity and personal records of patients and donors
should be kept conﬁdential, in accordance with fed-
eral, state, and local regulations. Medical records
management should not impair patient care.
5. Clinical Research
The transplant community has a responsibility to
foster activities that seek to improve outcomes for
transplant recipients and provide a scientiﬁc basis for
the standard of care.
Well-designed clinical trials conducted according
to good practices are essential for the practice of
medicine. Such research should proceed at the most
rapid pace possible. Patients should have access to
quality clinical trials, which often represent the most
appropriate treatment strategy for life-threatening
diseases.
6. Safety
The medical care provided for a transplant patient
should meet or exceed the standard set by the trans-
plant community.
To ensure maximum safety for the patient and the
donor, all blood and marrow transplant personnel
should be well trained and qualiﬁed to perform their
respective roles in cell collection, processing, and in-
fusion. Cellular products should be of high quality and
be equally available to every patient.
Transplant facilities should have an active quality
management program to ensure safe and effective
medical care. Facilities should participate in external
review and accreditation that independently docu-
ments that standards of care are being met.
Adverse events should be managed, tracked, eval-
uated, and readily available for study to improve pa-
tient safety.
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Government regulation is appropriate to protect
health and safety but should not place unnecessary,
arbitrary, or redundant burdens on transplant facili-
ties.
7. Education and Awareness
Advances in laboratory and clinical research must
be communicated rapidly to those providing patient
care.
The transplant community has a responsibility to
inform patients, families, other health professionals,
and the general public about new information that
might beneﬁt or otherwise have an impact on patients
or the public at large.
Greater awareness of blood and marrow trans-
plantation by patients, donors, health professionals,
payers, and the public is beneﬁcial for improving pa-
tient care, increasing donor interest, and diminishing
misinformation that might impede access to care.
—Adopted by the ASBMT Executive Committee on
August 21, 2003, and by the policy committees and/or
governing boards of the other ﬁve organizations during
the period of August-December 2003.
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